Shalby posts Rs 25.07 cr profit as Q1FY27 margin stands at 16.74%
The standalone result was filed after market close; depreciation and interest reduced operating profit before tax, while management outlined diversification plans.
Filed 12 Aug 2026, 19:04 IST · after market close · SHALBY (SHALBY)
Key takeaways
- Shalby reported standalone net profit of Rs 25.07 cr in Q1FY27, with EPS at Rs 2.33.
- Operating profit of Rs 42.49 cr translated into a 16.74% operating margin after Rs 211.30 cr of expenses.
- Depreciation of Rs 10.80 cr and interest of Rs 3.08 cr reduced operating profit before tax, while the tax rate was 26.03%.
Q1FY27 profit reflects the operating-to-PBT bridge
Shalby’s standalone operating profit of Rs 42.49 cr was reduced by Rs 10.80 cr of depreciation and Rs 3.08 cr of interest before reaching profit before tax of Rs 33.88 cr. Other income of Rs 5.28 cr partly offset those charges. Net profit was Rs 25.07 cr after a 26.03% tax rate.
Management links the next phase to diversification and cost control
Management said Shalby plans to maintain its global leadership in joint replacements while diversifying into cardiac science, oncology, neuroscience, critical care, general medicine and transplants. The company also said it plans to provide 24x7 homecare services through training and development. Its presentation identifies COGS reduction as a strategic pillar.
Results were filed after market close
The standalone results were filed at 19:04 IST on 12 August 2026, after market close. No market reaction was available when this note was prepared, so the quarter’s operating margin and the contribution of non-operating items remain the immediate reference points.
Q1FY27 at a glance
Standalone figures as filed with NSE — filed ahead of third-party databases, not yet independently cross-checked.
| Line item | Q1FY27 |
|---|---|
| Revenue | ₹254 cr |
| Other income | ₹5 cr |
| Expenses | ₹211 cr |
| Operating profit | ₹42 cr |
| Operating margin (%) | 16.74% |
| Interest | ₹3 cr |
| Depreciation | ₹11 cr |
| Profit before tax | ₹34 cr |
| Tax | ₹9 cr |
| Net profit | ₹25 cr |
| EPS (₹) | ₹2.33 |
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
Guidance & outlook
- Shalby plans to maintain global leadership in joint replacements.
- Shalby plans to diversify into cardiac science, oncology, neuroscience, critical care, general medicine and transplants.
New initiatives
- Shalby plans to provide 24x7 homecare services through training and development.
- Shalby identifies COGS reduction as a strategic pillar.
What to watch
- Whether operating margin holds above 16.74% in the next quarter.
- Whether COGS reduction changes the relationship between Rs 253.79 cr of revenue and Rs 211.30 cr of expenses.
- Progress in the planned expansion beyond joint replacements, including the 24x7 homecare initiative.